Buruli Ulcer: a Review of the Current Knowledge

Rie R. Yotsu, Koichi Suzuki, Rachel E. Simmonds, Roger Bedimo, Anthony Ablordey, Dorothy Yeboah-Manu, Richard Phillips, Kingsley Asiedu

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Purpose of the Review: Buruli ulcer (BU) is a necrotizing and disabling cutaneous disease caused by Mycobacterium ulcerans, one of the skin-related neglected tropical diseases (skin NTDs). This article aims to review the current knowledge of this disease and challenges ahead. Recent Findings: Around 60,000 cases of BU have been reported from over 33 countries between 2002 and 2017. Encouraging findings for development of point-of-care tests for BU are being made, and its treatment is currently in the transition period from rifampicin plus streptomycin (injection) to all-oral regimen. A major recent advance in our understanding of its pathogenesis has been agreement on the mechanism of action of the major virulence toxin mycolactone in host cells, targeting the Sec61 translocon during a major step in protein biogenesis. Summary: BU is distributed mainly in West Africa, but cases are also found in other parts of the world. We may be underestimating its true disease burden, due to the limited awareness of this disease. More awareness and more understanding of BU will surely contribute in enhancing our fight against this skin NTD.

Original languageEnglish (US)
JournalCurrent Tropical Medicine Reports
DOIs
StateAccepted/In press - Jan 1 2018

Fingerprint

Buruli Ulcer
Neglected Diseases
Mycobacterium ulcerans
Point-of-Care Systems
Skin
Western Africa
Streptomycin
Rifampin
Skin Diseases
Virulence
Injections
Proteins

Keywords

  • Buruli ulcer
  • Mycobacterium ulcerans
  • Mycolactone
  • Non-tuberculous mycobacterial disease
  • Skin neglected tropical diseases
  • Skin NTDs

ASJC Scopus subject areas

  • Immunology and Allergy
  • Infectious Diseases

Cite this

Yotsu, R. R., Suzuki, K., Simmonds, R. E., Bedimo, R., Ablordey, A., Yeboah-Manu, D., ... Asiedu, K. (Accepted/In press). Buruli Ulcer: a Review of the Current Knowledge. Current Tropical Medicine Reports. https://doi.org/10.1007/s40475-018-0166-2

Buruli Ulcer : a Review of the Current Knowledge. / Yotsu, Rie R.; Suzuki, Koichi; Simmonds, Rachel E.; Bedimo, Roger; Ablordey, Anthony; Yeboah-Manu, Dorothy; Phillips, Richard; Asiedu, Kingsley.

In: Current Tropical Medicine Reports, 01.01.2018.

Research output: Contribution to journalArticle

Yotsu, RR, Suzuki, K, Simmonds, RE, Bedimo, R, Ablordey, A, Yeboah-Manu, D, Phillips, R & Asiedu, K 2018, 'Buruli Ulcer: a Review of the Current Knowledge', Current Tropical Medicine Reports. https://doi.org/10.1007/s40475-018-0166-2
Yotsu, Rie R. ; Suzuki, Koichi ; Simmonds, Rachel E. ; Bedimo, Roger ; Ablordey, Anthony ; Yeboah-Manu, Dorothy ; Phillips, Richard ; Asiedu, Kingsley. / Buruli Ulcer : a Review of the Current Knowledge. In: Current Tropical Medicine Reports. 2018.
@article{248f6d50e7e24c499c383bb1be7555b7,
title = "Buruli Ulcer: a Review of the Current Knowledge",
abstract = "Purpose of the Review: Buruli ulcer (BU) is a necrotizing and disabling cutaneous disease caused by Mycobacterium ulcerans, one of the skin-related neglected tropical diseases (skin NTDs). This article aims to review the current knowledge of this disease and challenges ahead. Recent Findings: Around 60,000 cases of BU have been reported from over 33 countries between 2002 and 2017. Encouraging findings for development of point-of-care tests for BU are being made, and its treatment is currently in the transition period from rifampicin plus streptomycin (injection) to all-oral regimen. A major recent advance in our understanding of its pathogenesis has been agreement on the mechanism of action of the major virulence toxin mycolactone in host cells, targeting the Sec61 translocon during a major step in protein biogenesis. Summary: BU is distributed mainly in West Africa, but cases are also found in other parts of the world. We may be underestimating its true disease burden, due to the limited awareness of this disease. More awareness and more understanding of BU will surely contribute in enhancing our fight against this skin NTD.",
keywords = "Buruli ulcer, Mycobacterium ulcerans, Mycolactone, Non-tuberculous mycobacterial disease, Skin neglected tropical diseases, Skin NTDs",
author = "Yotsu, {Rie R.} and Koichi Suzuki and Simmonds, {Rachel E.} and Roger Bedimo and Anthony Ablordey and Dorothy Yeboah-Manu and Richard Phillips and Kingsley Asiedu",
year = "2018",
month = "1",
day = "1",
doi = "10.1007/s40475-018-0166-2",
language = "English (US)",
journal = "Current Tropical Medicine Reports",
issn = "2196-3045",
publisher = "Springer International Publishing AG",

}

TY - JOUR

T1 - Buruli Ulcer

T2 - a Review of the Current Knowledge

AU - Yotsu, Rie R.

AU - Suzuki, Koichi

AU - Simmonds, Rachel E.

AU - Bedimo, Roger

AU - Ablordey, Anthony

AU - Yeboah-Manu, Dorothy

AU - Phillips, Richard

AU - Asiedu, Kingsley

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Purpose of the Review: Buruli ulcer (BU) is a necrotizing and disabling cutaneous disease caused by Mycobacterium ulcerans, one of the skin-related neglected tropical diseases (skin NTDs). This article aims to review the current knowledge of this disease and challenges ahead. Recent Findings: Around 60,000 cases of BU have been reported from over 33 countries between 2002 and 2017. Encouraging findings for development of point-of-care tests for BU are being made, and its treatment is currently in the transition period from rifampicin plus streptomycin (injection) to all-oral regimen. A major recent advance in our understanding of its pathogenesis has been agreement on the mechanism of action of the major virulence toxin mycolactone in host cells, targeting the Sec61 translocon during a major step in protein biogenesis. Summary: BU is distributed mainly in West Africa, but cases are also found in other parts of the world. We may be underestimating its true disease burden, due to the limited awareness of this disease. More awareness and more understanding of BU will surely contribute in enhancing our fight against this skin NTD.

AB - Purpose of the Review: Buruli ulcer (BU) is a necrotizing and disabling cutaneous disease caused by Mycobacterium ulcerans, one of the skin-related neglected tropical diseases (skin NTDs). This article aims to review the current knowledge of this disease and challenges ahead. Recent Findings: Around 60,000 cases of BU have been reported from over 33 countries between 2002 and 2017. Encouraging findings for development of point-of-care tests for BU are being made, and its treatment is currently in the transition period from rifampicin plus streptomycin (injection) to all-oral regimen. A major recent advance in our understanding of its pathogenesis has been agreement on the mechanism of action of the major virulence toxin mycolactone in host cells, targeting the Sec61 translocon during a major step in protein biogenesis. Summary: BU is distributed mainly in West Africa, but cases are also found in other parts of the world. We may be underestimating its true disease burden, due to the limited awareness of this disease. More awareness and more understanding of BU will surely contribute in enhancing our fight against this skin NTD.

KW - Buruli ulcer

KW - Mycobacterium ulcerans

KW - Mycolactone

KW - Non-tuberculous mycobacterial disease

KW - Skin neglected tropical diseases

KW - Skin NTDs

UR - http://www.scopus.com/inward/record.url?scp=85054171224&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85054171224&partnerID=8YFLogxK

U2 - 10.1007/s40475-018-0166-2

DO - 10.1007/s40475-018-0166-2

M3 - Article

C2 - 30460172

AN - SCOPUS:85054171224

JO - Current Tropical Medicine Reports

JF - Current Tropical Medicine Reports

SN - 2196-3045

ER -